ACE-031GH BoosterSafety Rating 5/10

Primary research areaMuscle wasting diseases (Duchenne MD

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose rangeClinical trials: 1–3 mg/kg SC monthly. Research compound.
AdministrationVaries
Safety5/10 · Not FDA-approved (trials halted)
NCAA D1Banned

Price Comparison

Compare vendors

5 vendors competing

VendorPrice$ / mgUpdated
Pantheon PeptidesBest $/mgCOA ✓ · 3P$87.48$97.20−10% · code PEPTIDEPRI10$87.48Apr 23, 2026Buy →
Swiss ChemsCOA ✓ · 3P$138.95$138.95Apr 17, 2026Buy →
$25 off $100+·auto
Biotech PeptidesCOA unknown$161.00$161.00May 14, 2026Buy →
Behemoth LabzCOA ✓ · 3P$170.86$170.86May 14, 2026Buy →
Core PeptidesCOA ✓ · 3P$173.00$173.00Apr 16, 2026Buy →

Overview

About ACE-031

Mechanism of action

Fusion protein of activin receptor IIB and Fc; sequesters myostatin, activin A/B, GDF-8/11, and BMP9; broad inhibition of TGF-β superfamily ligands that suppress muscle growth.

Safety profile

Nosebleeds, gum bleeding, telangiectasias, spider veins (vasculature effects); muscle cramping; trials halted due to these effects. Significant risk profile. · Trials paused due to minor vascular effects (nosebleeds, telangiectasias); generally tolerated at lower doses

📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on ACE-031

Failed to fetch